A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Briz-Redón Á, Serrano-Aroca Á. The effect of climate on the spread of the COVID-19 pandemic: a review of findings, and statistical and modeling techniques. Prog. Phys. Geog: Earth Environ. 44(5), 591–604 (2020).
  Google Scholar
• 2. Briz-Redón Á, Serrano-Aroca Á. A Spatio-temporal analysis for exploring the effect of temperature on COVID-19 early evolution in Spain. Sci. Total Environ. 728 (2020).
  MedlineGoogle Scholar
• 3. Lundstrom K, Barh D, Uhal BD, Takayama K, Aljabali AAA, Abd El-Aziz TM et al. COVID-19 vaccines and thrombosis-roadblock or dead-end street? Biomolecules. 11(7), 1020 (2021).
  Medline CASGoogle Scholar
• 4. Briz-Redón Á, Serrano-Aroca Á. On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain. Stoch. Environ. Res. Risk Assess. 5, 1–8 (2022).
  Google Scholar
• 5. World Health Organization. WHO Coronavirus Disease Dashboard (Accessed 9 August 2021). https://covid19.who.int/
  Google Scholar
• 6. Hassan SS, Ghosh S, Attrish D, Choudhury PP, Aljabali AAA, Uhal BD et al. Possible transmission flow of SARS-CoV-2 based on ACE2 features. Molecules. 25(24), 5906 (2020).
  CASGoogle Scholar
• 7. Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Eng. J. Med. 382, 727–733 (2020).
  Medline CASGoogle Scholar
• 8. Zhou H, Chen X, Hu T et al. A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr. Biol. 30, 2196–2203.e3 (2020).
  Medline CASGoogle Scholar
• 9. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 16, 181(2), 271–280.e8 (2020).
  Google Scholar
• 10. Cao C, Cai Z, Xiao X et al. The architecture of the SARS-CoV-2 RNA genome inside the virion. Nat. Commun. 12, 3917 (2021).
  Medline CASGoogle Scholar
• 11. Chan JF, Kok KH, Zhu Z et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9(1), 221–236 (2020).
  Medline CASGoogle Scholar
• 12. Kim S, Lee JH, Lee S et al. The progression of SARS coronavirus 2 (SARS-CoV2): mutation in the receptor-binding domain of spike gene. Immune. Netw. 20(5), 41 (2020).
  Google Scholar
• 13. Bianchi M, Benvenuto D, Giovanetti M et al. SARS-CoV-2 envelope and membrane proteins: structural differences linked to virus characteristics? BioMed Res. Int. 4389089, 6 (2020).
  Google Scholar
• 14. Huang Y, Yang C, Xu XF et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141–1149 (2020).
  MedlineGoogle Scholar
• 15. Ou X, Liu Y, Lei X et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11(1), 1620 (2020).
  Medline CASGoogle Scholar
• 16. Donoghue M, Wakimoto H, Maguire CT et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with down-regulated connexins. J. Mol. Cell. Cardiol. 35(9), 1043–1053 (2003).
  Medline CASGoogle Scholar
• 17. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 176, 104742 (2020).
  Medline CASGoogle Scholar
• 18. Shang J, Wan Y, Luo C et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA. 117(21), 11727–11734 (2020).
  Medline CASGoogle Scholar
• 19. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl Acad. Sci. USA. 106(14), 5871–5876 (2009).
  Medline CASGoogle Scholar
• 20. GISAID. (2020). https://www.gisaid.org/
  Google Scholar
• 21. WHO. Track SARS-CoV-2 variants (2021). https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  Google Scholar
• 22. Centre for Disease Control and Prevention. COVID data tracker (2021). https://covid.cdc.gov/covid-data-tracker/#variant-proportions
  Google Scholar
• 23. European Centre for Disease Prevention and Control. Data on SARS-Cov-2 variants in the EU/EEA. https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-Covid-19-eueea
  Google Scholar
• 24. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184(9), 2384–2393.e12 (2021).
  Medline CASGoogle Scholar
• 25. Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). In: StatPearls. FL, USA (2022).
  Google Scholar
• 26. Li Q, Nie J, Wu J, Zhang L et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 184(9), 2362–2371.e9 (2021).
  Medline CASGoogle Scholar
• 27. Johnson BA, Xie X, Bailey AL et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293–299 (2021).
  Medline CASGoogle Scholar
• 28. Centre for Disease Control and Prevention. A New SARS-CoV-2 variant of concern identified: the Omicron (B.1.1.529) variant
  Google Scholar
• 29. Cascella M, Rajnik M, Cuomo A et al. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls FL, USA (2022).
  Google Scholar
• 30. Michigan State University. SARS CoV-2 Mutation Tracker. https://users.math.msu.edu/users/weig/SARS-CoV-2_Mutation_Tracker.html
  Google Scholar
• 31. Focosi D, Maggi F. Neutralising antibody escape of SARS‐CoV‐2 spike protein: risk assessment for antibody‐based COVID-19 therapeutics and vaccines. Rev. Med. Virol. 31(6), e2231 (2021).
  Medline CASGoogle Scholar
• 32. Jungreis I, Sealfon R, Kellis M. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat. Commun. 12, 2642 (2021).
  Medline CASGoogle Scholar
• 33. Hassan SS, Attrish D, Ghosh S et al. Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. Int. J. Biol. Macromols. 181, 801–809 (2021a). • It describes the architecture of ORF10 protein of SARS-CoV-2.
  Medline CASGoogle Scholar
• 34. Hassan SS, Lundstrom K, Barh D et al. Implications derived from S-protein variants of SARS-CoV-2 from six continents. Int. J. Biol. Macromols. 191, 934–955 (2021b). • It describes the demography-specific evolution of S protein.
  Medline CASGoogle Scholar
• 35. Hassan SS, Lundstrom K, Serrano-Aroca Á et al. Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function. Int. J. Biol. Macromols. 194, 128–143 (2022a). •• It reports the emergence of dominant mutations in different countries with the incidence of highly frequent mutations.
  Medline CASGoogle Scholar
• 36. Hassan SS, Lundstrom K, Serrano-Aroca Á et al. Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function. Int. J. Biol. Macromols. 194, 128–143 (2022b).
  Medline CASGoogle Scholar
• 37. Hirabara SM, Serdan TDA, Gorjao R et al. SARSCOV-2 variants: differences and potential of immune evasion. Front. Cell. Infect. Microbiol. 11, 781429 (2022).
  MedlineGoogle Scholar
• 38. Tegally H, Wilkinson E, Giovanetti M et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv. (2020). https://doi.org/10.1101/2020.12.21.20248640
  Google Scholar
• 39. Harvey WT, Carabelli AM, Jackson B et al. SARS-CoV-2 variants, spike mutations, and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021).
  Medline CASGoogle Scholar
• 40. Coronavirus Antiviral and Resistance Database. SARS-Cov-2 variants. https://covdb.stanford.edu/page/mutation-viewer
  Google Scholar
• 41. Kanekiyo M, Ellis D, King NP. New vaccine design and delivery technologies. J. Infect. Dis. 219(Suppl. 1), S88–S96 (2019).
  Medline CASGoogle Scholar
• 42. FDA. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber
  Google Scholar
• 43. Pfizer Pharmaceuticals. Pfizer and BioNTech granted FDA fast-track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2. https://www.pfizer.com/news/press-release/press-release-detail
  Google Scholar
• 44. European Pharmaceutical Review. FDA grants fast-track designation to two COVID-19 vaccines. https://www.europeanpharmaceuticalreview.com/
  Google Scholar
• 45. European Pharmaceutical Review. EMA to fast-track development of COVID-19 vaccines and therapeutics. http://www.europeanpharmaceuticalreview.com/news
  Google Scholar
• 46. Zhou H, Hen Y, Zhan S et al. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nat. Commun. 10, 3068 (2019).
  MedlineGoogle Scholar
• 47. Yu J, Tostanoski LH, Peter L et al. DNA vaccine protection against SARS-CoV-2 in Rhesus macaques. Science 369, 806–811 (2020).
  Medline CASGoogle Scholar
• 48. Bloomberg. More than 10.6 billion shots given: COVID-19 tracker. https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution
  Google Scholar
• 49. Robson F, Khan KS, Le TK et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol. Cell. 79(5), 710–727 (2020).
  Medline CASGoogle Scholar
• 50. Ju B, Jhang Q, Ge J et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119 (2020).
  Medline CASGoogle Scholar
• 51. Walls AC, Fiala B, Schäfer A et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183(5), 1367–1382 (2020).
  Medline CASGoogle Scholar
• 52. Gao Q, Bao L, Mao H et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).
  Medline CASGoogle Scholar
• 53. Voysey M, Clemens SAC, Madhi SA, Wecks L, Folegatti PM. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269), 99–111 (2021).
  Medline CASGoogle Scholar
• 54. Yoo JH. What do we know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. Korean Med. Sci. 36, e54–e54 (2021).
  Medline CASGoogle Scholar
• 55. Khan KH. DNA vaccines: roles against diseases. Germs. 3, 26–35 (2013).
  Medline CASGoogle Scholar
• 56. Chavada VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev. Vaccines. 20(12), 1549–1560 (2021).
  MedlineGoogle Scholar
• 57. Bošnjak B, Stein S C, Willenzon S et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell. Mol. Immunol. 18(4), 936–944 (2021).
  Medline CASGoogle Scholar
• 58. Hansen J, Baum A, Pascal KE et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369(6506), 1010–1014 (2020).
  Medline CASGoogle Scholar
• 59. Planas D, Veyer D, Baidaliuk A et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
  Medline CASGoogle Scholar
• 60. Netzl A, Tureli S, LeGresley E et al. Analysis of SARS-CoV-2 omicron neutralization data up to 2021-12-22. BioRxiv. https://doi.org/10.1101/2021.12.31.474032 (2022) (Epub ahead of print). •• It describes the vaccine effectiveness and neutralization assays in the homologous or heterologous prime-boosted individuals.
  MedlineGoogle Scholar
• 61. Bernal JL et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. N. Eng. J. Med. 385, e92 (2021).
  MedlineGoogle Scholar
• 62. Dejnirattisai W, Zhou D, Supasa P et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184(11), 2939–2954.e9 (2021).
  Medline CASGoogle Scholar
• 63. Chen X, Chen Z, Azman AS et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin. Infect. Dis. 74 (4 )734 -742 (2022).
  Medline CASGoogle Scholar
• 64. Wang G L, Wang Z Y, Duan L J et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N. Engl. J. Med. 384(24), 2354–2356 (2021).
  Medline CASGoogle Scholar
• 65. Andrews N, Tessier E, Stowe J et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N. Engl. J. Med. 386, 340–350 (2022).
  Medline CASGoogle Scholar
• 66. Lau EH, Hui DS, Tsang OT et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. eClinicalMedicine. 41, 101174 (2021).
  MedlineGoogle Scholar
• 67. Schubert M, Bertoglio F, Steinke S, Heine PA et al. Human serum from SARS-CoV-2 vaccinated and COVID-19 patients show reduced binding to the RBD of SARS-CoV-2 omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants. BMC Med. 20(1), 102 (2022).
  Medline CASGoogle Scholar
• 68. Cameroni E, Saliba C, Bowen JE et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature 602, 664–670 (2021).
  MedlineGoogle Scholar
• 69. Lu L, Mok B, Chen L et al. Neutralization of SARS-CoV-2 omicron variant by sera from BNT8162b2 or coronavac vaccine recipients. Clin. Infect. Dis. ciab1041 doi: 10.1093/CID/ciab1041 (2021) (Epub ahead of print).
  MedlineGoogle Scholar
• 70. Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596(7871), 273–27 (2021).
  Medline CASGoogle Scholar
• 71. Tao PL, Tzou J, Nouhin RK et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757–773 (2021).
  Medline CASGoogle Scholar
• 72. Wu K, Werner AP, Moliva JI et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv. https://doi.org/10.1101/2021.01.25.427948 (2021) (Epub ahead of print).
  Google Scholar
• 73. Klinakis A, Cournia Z, Rampias T. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains. Comput. Struct. Biotechnol. J. 4(19), 5556–5567 (2021).
  Google Scholar
• 74. Ramesh S, Govindarajulu M, Parise RS et al. Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy. Vaccines. 9, 1195 (2021).
  CASGoogle Scholar
• 75. Kimura I, Kosugi Y, Wu J et al. The genotype to phenotype Japan (G2P-Japan) consortium, Akatsuki Saito, So Nakagawa, Kei Sato. Cell Reports doi: 10.1016/j.celrep.2021.110218 (2021) (Epub ahead of print).
  Google Scholar
• 76. Sarkar R, Lo M, Saha R, Dutta S, Sarkar MC. S glycoprotein diversity of the Omicron variant. MedRxiv. https://doi.org/10.1101/2021.12.04.21267284 (2021) (Epub ahead of print).
  Google Scholar
• 77. Colson P, Delerce J, Burel E et al. Emergence in southern France of a new SARS-CoV-2 variant harboring both N501Y and E484K substitutions in the spike protein. Arch. Virol. 167 1185–1190 (2022).
  Medline CASGoogle Scholar
• 78. Tada T, Zhou H, Dcosta BM et al. High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals. Cell Rep. 38(2), 110237 (2022).
  Medline CASGoogle Scholar
• 79. Stadtmüller M, Laubner A, Rost F et al. Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variants. doi:10.1101/2021.11.01.21265749 (2022).
  Google Scholar
• 80. Korber B, Fischer WM, Gnanakaran S et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. Cell. doi: 10.1016/j.cell.2020.06.043 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 81. Chaudhari AM, Kumar D, Joshi M, Patel A, Joshi C. E156G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.617.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escape. doi:10.1101/2021.06.07.447321 (2021) (Epub ahead of print).
  Google Scholar
• 82. Shen X, Tang H, McDanal C et al. C-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 29, 529–539 (2021).
  Medline CASGoogle Scholar
• 83. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of the spike protein. J. Med. Virol. 94, 1641–1649 (2022).
  Medline CASGoogle Scholar
• 84. Sinha S, Tam B, Wang MS. Altered interaction between RBD and ACE2 receptor contributes toward the increased transmissibility of SARS CoV-2 Delta, Kappa, Beta, and Gamma strains with RBD double mutations. Viruses. doi: 10.3390/v14010001 (2021) (Epub ahead of print).
  Google Scholar
• 85. Calcagnile M, Forgez P, Alifano M, Alifano P. The lethal triad: SARS-CoV-2 spike, ACE2 and TMPRSS2. Mutations in host and pathogen may affect the course of the pandemic. BioRxiv. https://doi.org/10.1101/2021.01.12.426365 (2021) (Epub ahead of print).
  Google Scholar
• 86. Maaroufi H. The N764K and N856K mutations in SARS-CoV-2 Omicron BA.1 S protein generate potential cleavage sites for SKI-1/S1P protease https://doi.org/10.1101/2022.01.21.477298 (2022) (Epub ahead of print).
  Google Scholar
• 87. Kemp SA, Collier DA, Datir RP et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277–282 (2021).
  Medline CASGoogle Scholar
• 88. Farkas C, Mella A, Haigh JJ. Large-scale population analysis of SARS-CoV-2 whole-genome sequences reveals host-mediated viral evolution with the emergence of mutations in the viral spike protein associated with elevated mortality rates. MedRxiv https://doi.org/10.1101/2020.10.23.20218511 (2020) (Epub ahead of print).
  Google Scholar
• 89. Liu DX, Liang JQ, Fung TS. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encyclopedia Virol. 2 428–440 (2021).
  Google Scholar
• 90. Peiris JS, Lai ST, Poon LL et al. SARS study group. Coronavirus as a possible cause of the severe acute respiratory syndrome. Lancet 361(9366), 1319–1325 (2003).
  Medline CASGoogle Scholar
• 91. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367(19), 1814–1820 (2012).
  Medline CASGoogle Scholar